---
title: "General Medicine Raises $120M Series B to Build a Healthcare Store"
description: "Andreessen Horowitz led General Medicine's $120 million Series B as the company expands a nationwide catalog for medications, labs, telehealth and specialist care."
date: 2026-10-06T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-general-medicine-120m-series-b
---

# General Medicine Raises $120M Series B to Build a Healthcare Store

> Andreessen Horowitz led General Medicine's $120 million Series B as the company expands a nationwide catalog for medications, labs, telehealth and specialist care.

General Medicine has raised **$120 million in Series B financing led by Andreessen Horowitz**, with participation from Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup. The round brings total funding to **$152 million**.

## What General Medicine is building

The company describes itself as a nationwide healthcare store. Its catalog includes more than 2,900 products and services across medications, laboratory tests, telehealth, specialist e-consults and selected in-person visits and procedures.

The product thesis is straightforward: let people search and compare care in a format closer to ecommerce, including upfront prices with and without insurance.

## Why the round stands out

A $120 million Series B is large for a healthcare marketplace. The capital reflects the difficulty of building a national healthcare transaction layer: provider networks, pricing, insurance workflows, clinical operations and compliance all have to work together.

The key question is whether General Medicine can become a repeat purchasing layer rather than a collection of one-off healthcare transactions. Evidence to watch includes repeat usage, breadth of covered services, provider economics and whether transparent pricing actually changes how consumers shop for care.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.